-
Sep 1, 2024 | 
onlinelibrary.wiley.com | Jenny Byrne |Frédéric Baron |Myriam Labopin |Sorbonne Paris France
CONFLICT OF INTEREST STATEMENT FB has received travel grants and/or speaker honoraria from Pfizer, Celgene, Abbvie, Novartis, and Sanofi. JV has received speaker honoraria from AbbVie and ExCellThera. The other authors declare that they have no relevant conflict of interest. REFERENCES 1, , , et al. Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukemia: long-term follow up of a phase III study. Am J Hematol. 2020; 95: 749-758.
-
Aug 23, 2024 | 
digitalcommons.library.tmc.edu | Jenny Byrne |Stephane de Botton |Pau Montesinos |Andre C Schuh
This open-label, randomized, phase 3 trial (NCT02577406) compared enasidenib, an oral IDH2 (isocitrate dehydrogenase 2) inhibitor, with conventional care regimens (CCRs) in patients aged ≥60 years with late-stage, mutant-IDH2 acute myeloid leukemia (AML) relapsed/refractory (R/R) to 2 or 3 prior AML-directed therapies.
-
Jul 17, 2024 | .html&sz=64)
fis.uke.de | Jenny Byrne |Romain Guièze |Linda Koster |Diderik-Jan Eikema
Research ExplorerPublicationsAllogeneic hematopoietic stem-cell transplantation for patie... Abstract Bibliographical data
-
Mar 11, 2024 | 
onlinelibrary.wiley.com | Jenny Byrne |Corinne De Lord |Gwynn Matthias
INTRODUCTION Next-generation targeted sequencing (NGS) is an established diagnostic tool for haematological malignancies. NGS is performed by aligning the sequenced reads to the genome reference sequence and reporting discovered differences. One limitation of this approach is the inherent heterogeneity of germline genetics, which results in the inability to unambiguously determine whether any differences detected between tumour and reference are germline or somatic in origin.
-
Mar 11, 2024 | 
pericles.pericles-prod.literatumonline.com | Jenny Byrne |Corinne De Lord |Gwynn Matthias
INTRODUCTION Next-generation targeted sequencing (NGS) is an established diagnostic tool for haematological malignancies. NGS is performed by aligning the sequenced reads to the genome reference sequence and reporting discovered differences. One limitation of this approach is the inherent heterogeneity of germline genetics, which results in the inability to unambiguously determine whether any differences detected between tumour and reference are germline or somatic in origin.
-
Oct 2, 2023 | 
onlinelibrary.wiley.com | Jenny Byrne |Frédéric Baron |Arnon Nagler |Jacques-Emmanuel Galimard
CONFLICT OF INTEREST STATEMENT FB has received travel grants and/or speaker honoraria from Celgene, Abbvie, Novartis, Pfizer and Sanofi. The other authors declare that they have no relevant conflict of interest. REFERENCES 1, . Optimizing outcomes in secondary AML. Hematology Am Soc Hematol Educ Program. 2022; 2022: 23–29. 2, , , , , , et al. Survival improvement over time of 960 s-AML patients included in 13 EORTC-GIMEMA-HOVON trials. Cancer. 2020; 12(11): 3334. 3, , , , , , et al.
-
Jul 13, 2023 | 
pubmed.ncbi.nlm.nih.gov | Jenny Byrne |Piñana JL |Cornelissen JJ |Pascual MJ
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
-
Jul 13, 2023 | 
academic.oup.com | Jenny Byrne |jose luis |Fundación INCLIVA |Universitario de Valencia
-
Jun 12, 2023 | 
pubmed.ncbi.nlm.nih.gov | Jenny Byrne |Huang YJ |Chan YLT |O'Nions J
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
-
Jun 12, 2023 | 
onlinelibrary.wiley.com | Jenny Byrne |Justin Loke |Vinit Upasani
SHORT REPORT Justin Loke and Vinit Upasani contributed equally as joint first authors. Simon J. Stanworth and David M. Lowe—joint senior authors. Summary Limited data exist on COVID-19 vaccination efficacy in patients with acute myeloid leukemia and myelodysplasia with excess blasts (AML/MDS-EB2). We report results from a prospective study, PACE (Patients with AML and COVID-19 Epidemiology). 93 patients provided samples post-vaccine 2 or 3 (PV2, PV3).
